常州千红生化制药股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为常州千红生化制药股份有限公司（以下简称"公司"）的独立董事， 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《独立董事工作制度》 等相关法律、法规以及《公司章程》等有关规定和要求，认真履行职责，谨慎、 勤勉地行使公司所赋予的权利，充分发挥独立董事的独立性作用，维护了公司的 整体利益和全体股东特别是社会公众股股东的合法权益。现将 2024 年度本人履 行独立董事职责情况述职如下： 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律法规中对独立董事独立性的相关要求，不存在影响独立性的情况。 二、独立董事度履职概况 （一）2024 年度出席董事会和股东大会的情况 2024 年度，公司共召开 8 次董事会，本人应出席 8 次，实际出席 8 次；公 司召开 4 次股东大会，本人因工作原因未能参加股东大会。 本人积极履行独立董事的义务。历次董事会会前，本人认真阅读和研究议案， 并以谨慎的态度行使表决权，维护了公司的整 ...

常州千红生化制药股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为常州千红生化制药股份有限公司（以下简称"公司"）的独立董事， 按照《公司法》、《证券法》、《上市公司独立董事管理办法》、《独立董事工作制度》 等相关法律、法规以及《公司章程》等有关规定和要求，认真履行职责，谨慎、 勤勉地行使公司所赋予的权利，充分发挥独立董事的独立性作用，维护了公司的 整体利益和全体股东特别是社会公众股股东的合法权益。现将 2024 年度本人履 行独立董事工作职责情况述职如下： 一、独立董事的基本情况 （一）工作履历、专业背景及兼职情况 本人宁敖，中国国籍，无境外永久居留权，1961 年出生，硕士学历。最近五 年曾任华泰联合证券有限责任公司执行委员会委员、工会主席、董事总经理及保 荐代表人，常州千红生化制药股份有限公司独立董事。现任公司独立董事。 （二）独立性自查及说明 作为公司的独立董事，经自查，本人符合《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 相关法律法规中对独立董事独立性的相关要求，不存在影响独立性的情况。 本人积极履行独立董事的 ...

因此，公司独立董事宁敖先生、任胜祥先生、高玉玉女士满足独 立董事任职要求，不存在影响独立性的情形，符合《上市公司独立董 事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等规则中独立董事独立性的相关规定。 常州千红生化制药股份有限公司 董 事 会 2025 年 04 月 19 日 常州千红生化制药股份有限公司董事会 关于独立董事 2024 年度保持独立性情况的专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等规定要求，常州 千红生化制药股份有限公司（以下简称"公司"）董事会就公司 2024 年度在任独立董事宁敖先生、任胜祥先生、高玉玉女士的独立性情况 进行评估并出具如下专项意见： 经核查三位独立董事的任职经历以及相关自查文件，上述人员未 在公司担任除独立董事以外的其他职务，也未在公司控股股东、实际 控制人控制的企业担任任何职务；并与公司及公司控股股东、实际控 制人以及其他董事、监事、高级管理人员不存在直接或者间接利益关 系，或者其他可能影响其进行独立客观判断的关系。 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥450,880,337.41, a decrease of 2.22% compared to ¥461,101,487.65 in the same period last year[6] - Net profit attributable to shareholders increased by 54.62% to ¥160,968,397.92 from ¥104,108,160.35 year-on-year[6] - Basic and diluted earnings per share rose by 55.74% to ¥0.1288 from ¥0.0827 in the same period last year[6] - Total operating revenue for the current period is $450.88 million, a decrease of 2.6% from $461.10 million in the previous period[19] - Net profit for the current period is $157.61 million, an increase of 55.6% compared to $101.35 million in the previous period[20] Cash Flow - The net cash flow from operating activities decreased by 58.21% to ¥71,511,688.25, down from ¥171,109,914.54 in the previous year[6] - Cash flow from operating activities generated a net amount of $71.51 million, a decrease of 58.3% from $171.11 million in the previous period[22] - The company reported a net increase of ¥46,901,300 in cash flow from investing activities, attributed to maturing bank financial products[10] - Cash flow from investing activities generated a net amount of $127.99 million, an increase from $81.09 million in the previous period[22] Assets and Liabilities - Total assets increased by 4.16% to ¥2,948,304,157.01 compared to ¥2,830,441,261.34 at the end of the previous year[6] - The company's cash and cash equivalents increased to ¥638,549,089.41 from ¥439,945,400.01, representing a growth of approximately 45.2%[16] - The company's total liabilities decreased to ¥274,026,522.27 from ¥313,870,622.96, reflecting a reduction of approximately 12.7%[17] - Total assets rose to ¥2,948,304,157.01, up from ¥2,830,441,261.34, indicating an increase of about 4.2%[17] - The total equity attributable to the parent company increased to ¥2,678,508,814.41 from ¥2,517,442,607.50, marking a growth of around 6.4%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 57,296, with the largest shareholder holding 19.96% of the shares[12] Inventory and Receivables - Accounts receivable rose to ¥311,016,437.94 from ¥254,387,636.49, which is an increase of approximately 22.2%[16] - Inventory decreased to ¥367,041,802.35 from ¥426,812,563.07, showing a decline of about 13.9%[16] Other Financial Metrics - The weighted average return on equity improved to 6.20%, up from 4.31% year-on-year, reflecting better profitability[6] - The company recovered overdue payments from the Jian Yuan Trust, contributing to the significant increase in net profit[9] - The decrease in revenue was primarily due to a decline in the export price of raw materials compared to the previous year[9] - The company experienced a significant increase in credit impairment losses, totaling $52.62 million, compared to a reversal of $6.06 million in the previous period[19] - The company reported a tax expense of $29.43 million, compared to $15.49 million in the previous period, reflecting an increase of 90.1%[20] - Other comprehensive income after tax for the current period is $97,808.99, compared to a loss of $1.32 million in the previous period[20]

Financial Performance - The company's operating revenue for 2024 was ¥1,526,242,786.73, a decrease of 15.88% compared to ¥1,814,268,908.89 in 2023 [22]. - The net profit attributable to shareholders for 2024 was ¥356,032,007.44, representing a significant increase of 95.77% from ¥181,860,747.32 in 2023 [22]. - The net profit after deducting non-recurring gains and losses was ¥268,999,200.65, up 87.48% from ¥143,482,106.21 in 2023 [22]. - The basic earnings per share for 2024 was ¥0.28, doubling from ¥0.14 in 2023 [22]. - The total assets at the end of 2024 were ¥2,830,441,261.34, an increase of 2.33% from ¥2,766,081,444.15 at the end of 2023 [22]. - The net assets attributable to shareholders at the end of 2024 were ¥2,517,442,607.50, up 2.55% from ¥2,454,931,005.01 at the end of 2023 [22]. - The company reported a cash flow from operating activities of ¥514,709,074.46, a slight decrease of 3.49% from ¥533,327,999.55 in 2023 [22]. - The total operating revenue for 2024 was approximately ¥1.53 billion, a decrease of 15.88% compared to ¥1.81 billion in 2023 [71]. - The biopharmaceutical segment accounted for 99.75% of total revenue, with a revenue of approximately ¥1.52 billion, down 15.72% year-on-year [71]. - The raw material drug series generated approximately ¥443.40 million, representing 29.05% of total revenue, with a significant decline of 35.93% compared to the previous year [71]. - The formulation series contributed approximately ¥1.08 billion, making up 70.70% of total revenue, with a slight decrease of 3.18% year-on-year [71]. - Domestic sales accounted for 76.93% of total revenue, amounting to approximately ¥1.17 billion, down 6.61% from the previous year [71]. - International sales decreased by 36.79%, totaling approximately ¥352.11 million, which represented 23.07% of total revenue [71]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.2 CNY per 10 shares to all shareholders, based on a total of 1,249,800,000 shares [5]. - The company distributed cash dividends of 1.2 yuan per 10 shares to all shareholders, resulting in cash dividends of 460,000 yuan for the first phase employee stock ownership plan and 3.38 million yuan for the 2022 core employee stock ownership plan [168]. - The company reported a total distributable profit of RMB 1,042,060,518.73 for the year 2024 [163]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution [163]. Research and Development - The company is actively involved in research and development of new products and technologies, particularly in the biopharmaceutical sector [20]. - The company has established a comprehensive innovation system, with four innovative drugs currently undergoing or about to enter Phase II clinical trials, enhancing its core competitiveness [33]. - The company has several new drug projects in clinical trials, including QHRD107 and QHRD106, aimed at enhancing the product pipeline and core competitiveness [83]. - The company is committed to utilizing AI and other new technologies to empower drug design, clinical trials, and commercialization processes [31]. - R&D investment increased by 9.92% year-over-year, from ¥137,259,386.30 in 2023 to ¥150,875,539.72 in 2024, representing 9.89% of operating revenue [84]. - Capitalized R&D investment rose by 15.56% from ¥40,175,940.29 in 2023 to ¥46,428,333.75 in 2024, accounting for 30.77% of total R&D investment [84]. Market Position and Strategy - The company has expanded its market presence and is exploring opportunities for mergers and acquisitions to enhance its competitive edge [20]. - The company is positioned in a high-quality development phase within the pharmaceutical sector, focusing on innovative drugs and biotechnology [30]. - The company is a leading enterprise in the domestic biopharmaceutical industry, focusing on innovative drugs and maintaining a leading market share in heparin sodium injection and sealing liquid [32]. - The company is actively expanding its international market presence, particularly in low molecular weight heparin products, with steady growth in export volumes [63]. - The company plans to enhance domestic market share by innovating marketing strategies, particularly for core products like heparin and low molecular weight heparin preparations [102]. - The company is committed to expanding its overseas market presence, particularly in the heparin sector, to optimize export structures and increase market share [103]. Risk Management - The company has detailed potential risks and corresponding countermeasures in the report, particularly in the section discussing future development prospects [5]. - The implementation of drug procurement policies poses a significant risk of declining sales prices, which could adversely affect the company's operating performance [108]. - The heparin business is facing risks due to decreased demand in major overseas markets, leading to potential sales performance decline [109]. - Increased investment in new drug research and development presents risks to operating profits due to the lengthy and costly nature of the process [110]. - Stricter environmental policies add uncertainty and risk to the company's operations, despite having adequate environmental management facilities [111]. - Rising operational costs due to fluctuations in raw material prices, increased labor costs, and new drug development expenses pose risks to profitability [113]. - The management is committed to minimizing risks through comprehensive risk control measures and improving governance capabilities to adapt to market changes [113]. Corporate Governance - The company has maintained compliance with corporate governance regulations, with no unresolved governance issues reported [120]. - The board of directors has established four specialized committees to provide professional opinions and references for decision-making [121]. - The company has a clear organizational structure, with independent operation of its governance framework, ensuring no interference from the controlling shareholder [126]. - The company has an independent financial accounting department and has established a separate accounting system, ensuring independent financial decision-making [126]. - The company has implemented a comprehensive investor relations management strategy, enhancing communication with investors through multiple channels [123]. - The company emphasizes the importance of talent acquisition and retention to support its development and operational management [113]. Environmental Compliance - The company strictly complies with environmental protection laws and standards, including the Environmental Protection Law of the People's Republic of China and various local regulations [175]. - The Jiangsu Changjiang Road plant has established a wastewater treatment station that meets discharge standards, with wastewater treated through physical and biological processes [177]. - The company has implemented an automatic monitoring system for wastewater discharge, including COD, total nitrogen, pH, and flow rate measurements [178]. - The company reported that all monitored pollution indicators met discharge standards in 2024, as verified by third-party testing [178]. - The company incurred environmental expenses of approximately RMB 4.5817 million during the reporting period, including investments in environmental facilities and pollutant treatment [179]. Employee Management - The company has a total of 979 employees, with 411 in sales, 275 in production, and 188 in technical roles [154]. - The company has implemented a diverse training program for employees, including onboarding and ongoing professional development [157]. - The company has a strong governance structure with a diverse board of directors and supervisory committee members, ensuring effective oversight [135][139]. - The company emphasizes the importance of aligning management compensation with overall company performance to drive growth and accountability [140].

千红制药（002550）公告，2024年营业收入15.26亿元，同比下降15.88%。归属于上市公司股东的净利 润3.56亿元，同比增长95.77%。公司经本次董事会审议通过的利润分配预案为：以12.5亿为基数，向全 体股东每10股派发现金红利1.2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

证券代码：002550 证券简称：千红制药 公告编号：2025-002 公司于近日收到持股 5%以上大股东赵刚先生及其一致行动人赵人谊女士、 建信基金-赵人谊-建信鑫享 1 号单一资产管理计划出具的《关于减持公司股份计 划的告知函》，现将有关情况公告如下： 常州千红生化制药股份有限公司 关于持股 5%以上股东及其一致行动人减持股份预披露公告 持股 5%以上的股东赵刚先生及其一致行动人赵人谊、建信基金- 赵人谊-建信鑫享 1 号单一资产管理计划均保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 特别提示： 合计持有常州千红生化制药股份有限公司（以下简称"公司"或"本公司"） 股份 98,301,000 股（占公司目前总股本比例 7.68%，占公司剔除回购专用账户 持股数量的总股本比例 7.87%）的大股东赵刚先生及其一致行动人赵人谊女士、 建信基金-赵人谊-建信鑫享 1 号单一资产管理计划，计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价交易方式或大宗交易方式减持本公司股份 不超过 37,494, ...

Financial Performance - The net profit attributable to shareholders is expected to be between 32,000 and 38,000 million CNY, representing a year-on-year increase of 75.96% to 108.95% compared to 18,186.07 million CNY last year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 25,000 and 30,000 million CNY, reflecting a growth of 74.24% to 109.09% from 14,348.21 million CNY in the previous year[3] - Basic earnings per share are anticipated to be between 0.25 and 0.30 CNY, up from 0.14 CNY in the same period last year[3] Sales and Profitability - The company has achieved significant profit growth despite a decline in sales revenue due to falling drug prices, with major product sales volume continuing to increase and gross margin improving compared to the previous year[4] Non-recurring Items - Non-recurring gains and losses for the reporting period are estimated at approximately 85 million CNY, primarily due to a settlement agreement with Jianyuan Trust, resulting in a payment of 85 million CNY[5] Cautionary Note - The company emphasizes that the earnings forecast is based on preliminary calculations and has not been audited by an accounting firm, urging investors to exercise caution[6]

北 京 大 成 （ 南 京 ） 律 师 事 务 所 关 于 常 州 千 红 生 化 制 药 股 份 有 限 公 司 2 024 年 第 三 次临时 股 东 大 会 的 法 律 意 见 书 北 京 大 成 （ 南 京 ） 律 师 事 务 所 南京市鼓楼区集慧路 18 号联创科技大厦 A 座 7-11 楼 联系电话：028-83755000 传真：025-83755111 邮编：210036 北京大成（南京）律师事务所关于常州千红生化制药股份有限 公司 2024 年第三次临时股东大会的法律意见书 致：常州千红生化制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法 规和其他有关规范性文件的要求，北京大成（南京）律师事务所（以下简称"本 所"）接受常州千红生化制药股份有限公司（以下简称"公司"）的委托，指派 律师参加公司 2024 年第三次临时股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-055 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2024 年 12 月 10 日（周二）下午 14:00 2、网络投票时间：2024 年 12 月 10 日 常州千红生化制药股份有限公司 2024 年第三次临时股东大会决议公告 （二）公司部分董事、监事、高级管理人员以及见证律师出席或列席了本次 股东大会。 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 12 月 10 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 12 月 10 日上午 9:15 至下午 15:00 期间的任意时间。 （二）召开地点：公司云河路厂区二楼会议室（江苏省常州市新北区云河路 518 号） （三）召开方式：现场与网络会议方式 （四） ...